Drugs that target CSCs, such as metformin, may exhibit efficacy similar to anti-angiogenic therapies, which is due to the reduction in the proportion of CD44+/CD117+ CSCs and the alleviation of hypoxia in the tumor microenvironment [133,151]. This evidence concerns the gene CD44 and neoplasm.